ARD-2585

Cat. No. M21192

All AbMole products are for research use only, cannot be used for human consumption.

For this product's availability, delivery time and price, please email [email protected] directly or click the "Inquiry Now" button below.

ARD-2585 is a potent, orally active PROTAC reducer of the androgen receptor.

Molecular Weight	763.28
Formula	C41H43ClN8O5
Solubility (25°C)	DMSO ≥ 60 mg/mL
Storage	-20°C, protect from light, dry, sealed

Related PROTAC Products
ML 2-14 ML 2-14 is a E3-recruiting (RNF114, RNF4)-based PROTAC. ML 2-14 is targeting BRD4 with a C4 alkyl linker. ML 2-14 consists of the E3 ligase ligand EN219, the target protein ligand JQ-1, and the PROTAC linker. ML 2-14 can effectively degrade BRD4 in 231MFP breast cancer cells.
GDC-2992 GDC-2992 is an orally active androgen receptor (AR) degrader. GDC-2992 degrads AR with a DC50 value of 2.7 nM and inhibits proliferation with an IC50 valude of 9.7 nM in VCaPcells.
Setidegrasib Setidegrasib is a PROTAC KRAS degrader (DC50: 37 nM). Setidegrasib induces the degradation of G12D-mutation KRAS protein. Setidegrasib has antitumor effect.
PROTAC HK2 Degrader-1 PROTAC HK2 Degrader-1 is a PROTAC consisting of Lonidamine as a target protein Hexokinase 2 (HK2) inhibitor and Thalidomide as a CRBN ligand-linked PROTAC. PROTAC HK2 Degrader-1 selectively inhibits the proliferation of breast cancer cells by forming a ternary complex through the ubiquitin-proteasome system to degrade Hexokinase 2 (HK2) protein leading to mitochondrial damage and cell death.
ZXH-4-130 TFA ZXH-4-130 TFA is a highly potent and selective degrader of CRBN. ZXH-4-130 is a CRBN-VHL compound (hetero-PROTAC).

Catalog